Stock Watch: The Mixed History Of Biotech Company Separations
Was Bluebird’s Split Accompanied By Premature Enthusiasm?
Executive Summary
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
You may also be interested in...
Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
Stock Watch: Biogen, Blood In The Water
When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.
Stock Watch: When Governments Step In
Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.